psilocybin (PSIL428) / Wake Network - LARVOL DELTA

Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Wake Network, Inc. | N=120 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • CNS Disorders • Depression • Mood Disorders • Psychiatry

Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Wake Network, Inc. | Trial completion date: Aug 2022 ➔ Aug 2023 | Initiation date: Sep 2021 ➔ Sep 2022 | Trial primary completion date: Jun 2022 ➔ Jun 2023

Trial completion date • Trial initiation date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry

Wake Network, Inc. Receives Certificate of Drug Registration for Microdose Formulation in Jamaica (Yahoo Finance) - "Wake Network, Inc...is pleased to announce the Company has received a Certificate of Drug Registration from the Jamaican Ministry of Health & Wellness for its naturally derived psilocybin microdose formulation, PSIL428....PSIL 428 will be used in Wake's double-blind, randomized, placebo-controlled clinical trial assessing the effects of microdosing on anxiety and depression."

New trial • CNS Disorders • Depression • General Anxiety Disorder